Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
2019 |
| gptkbp:ATCCode |
gptkb:L01FX16
|
| gptkbp:CASNumber |
2089217-15-8
|
| gptkbp:combinationTherapy |
gptkb:rituximab
gptkb:bendamustine |
| gptkbp:contains |
gptkb:monomethyl_auristatin_E
|
| gptkbp:developedBy |
gptkb:Genentech
|
| https://www.w3.org/2000/01/rdf-schema#label |
polatuzumab vedotin-piiq
|
| gptkbp:indication |
relapsed or refractory diffuse large B-cell lymphoma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Roche
|
| gptkbp:mechanismOfAction |
delivers cytotoxic agent to B-cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
fever diarrhea peripheral neuropathy neutropenia thrombocytopenia |
| gptkbp:target |
gptkb:CD79b
|
| gptkbp:usedFor |
diffuse large B-cell lymphoma
|
| gptkbp:bfsParent |
gptkb:Polivy
|
| gptkbp:bfsLayer |
7
|